Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma

Cabozantinib is an oral, tyrosine-kinase inhibitor with potent activity against VEGFR2 and MET, along with multiple other tyrosine kinases involved in cancer development and progression. Herein, we will focus on preclinical and clinical studies leading to the approval of cabozantinib in advanced ren...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathi, Nityam, Maughan, Benjamin L, Agarwal, Neeraj, Swami, Umang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246323/
https://www.ncbi.nlm.nih.gov/pubmed/32547210
http://dx.doi.org/10.2147/CMAR.S202973
_version_ 1783537919460376576
author Rathi, Nityam
Maughan, Benjamin L
Agarwal, Neeraj
Swami, Umang
author_facet Rathi, Nityam
Maughan, Benjamin L
Agarwal, Neeraj
Swami, Umang
author_sort Rathi, Nityam
collection PubMed
description Cabozantinib is an oral, tyrosine-kinase inhibitor with potent activity against VEGFR2 and MET, along with multiple other tyrosine kinases involved in cancer development and progression. Herein, we will focus on preclinical and clinical studies leading to the approval of cabozantinib in advanced renal cell carcinoma and hepatocellular carcinoma. Covered studies include NCT01100619, CABOSUN, METEOR, NCT00940225 and the CELESTIAL trial. Finally, we review future directions of cabozantinib development by highlighting some ongoing clinical trials.
format Online
Article
Text
id pubmed-7246323
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72463232020-06-15 Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma Rathi, Nityam Maughan, Benjamin L Agarwal, Neeraj Swami, Umang Cancer Manag Res Review Cabozantinib is an oral, tyrosine-kinase inhibitor with potent activity against VEGFR2 and MET, along with multiple other tyrosine kinases involved in cancer development and progression. Herein, we will focus on preclinical and clinical studies leading to the approval of cabozantinib in advanced renal cell carcinoma and hepatocellular carcinoma. Covered studies include NCT01100619, CABOSUN, METEOR, NCT00940225 and the CELESTIAL trial. Finally, we review future directions of cabozantinib development by highlighting some ongoing clinical trials. Dove 2020-05-20 /pmc/articles/PMC7246323/ /pubmed/32547210 http://dx.doi.org/10.2147/CMAR.S202973 Text en © 2020 Rathi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Rathi, Nityam
Maughan, Benjamin L
Agarwal, Neeraj
Swami, Umang
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
title Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
title_full Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
title_fullStr Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
title_full_unstemmed Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
title_short Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
title_sort mini-review: cabozantinib in the treatment of advanced renal cell carcinoma and hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246323/
https://www.ncbi.nlm.nih.gov/pubmed/32547210
http://dx.doi.org/10.2147/CMAR.S202973
work_keys_str_mv AT rathinityam minireviewcabozantinibinthetreatmentofadvancedrenalcellcarcinomaandhepatocellularcarcinoma
AT maughanbenjaminl minireviewcabozantinibinthetreatmentofadvancedrenalcellcarcinomaandhepatocellularcarcinoma
AT agarwalneeraj minireviewcabozantinibinthetreatmentofadvancedrenalcellcarcinomaandhepatocellularcarcinoma
AT swamiumang minireviewcabozantinibinthetreatmentofadvancedrenalcellcarcinomaandhepatocellularcarcinoma

Ejemplares similares